CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 348 enrolled
Drug / intervention
Saxagliptin +3 moredrug
Likely dose
Saxagliptin 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02917031
NCT02917031Phase 4Completed
CompareCT.gov

A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure

AstraZeneca·interventional·Posted Sep 28, 2016·Updated Nov 8, 2021

In Brief

A Phase 4 clinical trial evaluating Saxagliptin, Sitagliptin, and 2 other interventions for Type 2 Diabetes Mellitus and Heart Failure. Completed, enrolled 348 participants across 74 sites in 10 countries.

Detailed Summary

This is a 24 week, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with type 2 diabetes (T2DM) mellitus and heart failure (HF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus, Heart Failure
CountriesBulgaria, Canada, Chile, Hungary, Romania, Russia, South Korea, Thailand, Ukraine, United States
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 28, 2016
Enrollment StartJan 10, 2017
Primary CompletionAug 23, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.8 years ago

Interventions

Saxagliptindrug

5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet

Sitagliptindrug

50 mg or 100 mg, gray capsule

Placebo to match saxagliptindrug

2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet

Placebo to match sitagliptindrug

50 mg or 100 mg, gray capsule